Allogene Therapeutics Inc logo

Allogene Therapeutics Inc

7
NAS:ALLO (USA)  
$ 2.09 +0.14 (+7.18%) 11:09 PM EST
At Loss
P/B:
0.94
Market Cap:
$ 408.86M
Enterprise V:
$ 185.66M
Volume:
1.81M
Avg Vol (2M):
2.66M
Trade In:
Volume:
1.81M
At Loss
Avg Vol (2M):
2.66M

Business Description

Allogene Therapeutics Inc logo
Allogene Therapeutics Inc
NAICS : 325414 SIC : 2836
ISIN : US0197701065
Description
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.
Name Current Vs Industry Vs History
Cash-To-Debt 3.43
Equity-to-Asset 0.79
Debt-to-Equity 0.18
Debt-to-EBITDA -0.33
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -3.12
Distress
Grey
Safe
Beneish M-Score -1.61
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 61.04
9-Day RSI 49.97
14-Day RSI 46.1
6-1 Month Momentum % -15.33
12-1 Month Momentum % -27.78

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 9.35
Quick Ratio 9.35
Cash Ratio 8.95

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -6.3
Shareholder Yield % 1.52

Financials (Next Earnings Date:2025-03-14 Est.)

ALLO's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:ALLO

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Allogene Therapeutics Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0.043
EPS (TTM) ($) -1.56
Beta 1.05
Volatility % 77.49
14-Day RSI 46.1
14-Day ATR ($) 0.174879
20-Day SMA ($) 2.16225
12-1 Month Momentum % -27.78
52-Week Range ($) 1.78 - 5.775
Shares Outstanding (Mil) 209.67

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Allogene Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Allogene Therapeutics Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Allogene Therapeutics Inc Frequently Asked Questions

What is Allogene Therapeutics Inc(ALLO)'s stock price today?
The current price of ALLO is $2.09. The 52 week high of ALLO is $5.78 and 52 week low is $1.78.
When is next earnings date of Allogene Therapeutics Inc(ALLO)?
The next earnings date of Allogene Therapeutics Inc(ALLO) is 2025-03-14 Est..
Does Allogene Therapeutics Inc(ALLO) pay dividends? If so, how much?
Allogene Therapeutics Inc(ALLO) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1